Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × capivasertib × Lymphoid × Clear all

Phase

Status

Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6 Genitourinary 2 Dermatologic 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 CNS 1

Conditions

Lymphoma 1 Leukemia 1

Interventions

Cyclophosphamide 157 Rituximab 136 venetoclax 78 fludarabine 74 Specimen Handling 62 obinutuzumab 61 Prednisone 61 Doxorubicin 61 Vincristine 60 Magnetic Resonance Spectroscopy 51 Lenalidomide 50 zanubrutinib 48 Biopsy 46 Dexamethasone 44 Cytarabine 40 Methotrexate 37 Bendamustine Hydrochloride 33 acalabrutinib 32 Etoposide 32 fludarabine phosphate 30 blinatumomab 29 ibrutinib 28 Immunotherapy, Adoptive 26 glofitamab 25 pirtobrutinib 24 polatuzumab vedotin 23 Gemcitabine 23 pembrolizumab 20 orelabrutinib 19 Injections 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡